Clinical trials: Hyperglycemias
Type 2 Diabetes
A Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD0186
This study will assess the safety, tolerability, and pharmacokinetics of AZD0186 following single ascending doses (SAD) via oral administration in healthy adult participants.
- Trial name
- NCT05694741
- Testing
- AZD0186
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabetes Mellitus
A Two Part Study of Peroral Insulin in Type 2 Diabetes
Insulin is normally not bioavailable when taken through the oral route, as degradation of the molecule may occur both in the ventricle and in the intestine.
- Trial name
- ORA2 (NCT00990444)
- Testing
- Insulin in Dextran Matrix
- Where
- Sweden
- Volunteers
- 32 people
- Sponsor
- Bows Pharmaceuticals AG
Blood Sugar; High, Overweight and Obesity
Effect of a Glucagon Like Peptide 1 (GLP1) Booster in Healthy Humans
BACKGROUND GLP1 booster (GB) was designed to stimulate the endogenous production of GLP1, which in turn releases insulin, controls blood glucose level, suppresses appetite and thus helps people lose weight.
- Conditions
- Blood Sugar; High, Overweight and Obesity, Fat Burn, Obesity
- Trial name
- NCT06333496
- Testing
- GLP-1 Booster (GB)
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Alpine Biotech LLC
Prediabetic State, Diabetes type2
Effect of Totum-63 on Glucose and Lipid Homeostasis in Subjects With Dysglycemia (REVERSE-IT)
This clinical study aims to assess the efficacy of TOTUM-63, a mix of 5 plant extracts, consumed at the daily regimen of three times per day on glucose and lipid homeostasis in dysglycemic subjects.
- Conditions
- Prediabetic State, Diabetes type2, Dysglycemia
- Trial name
- REVERSE-IT (NCT04423302)
- Testing
- TOTUM-63 3 intakes per day, TOTUM-63 2 intakes per day
- Where
- 52 sites in Bulgaria, France and 5 more
- Volunteers
- 636 people, healthy volunteers welcome
- Sponsor
- Valbiotis
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy
The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, used in a 2-step dose titration regimen in monotherapy, over a period of 12 weeks of treatment.
- Trial name
- GETGOAL-MONO (NCT00688701)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector
- Where
- 12 sites in United States, Belgium and 10 more
- Volunteers
- 361 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus, Hyperglycemia
Ex Vivo Immunotherapy for Hyperglycemia in Type 2 Diabetes Mellitus
Diabetes mellitus type 2 is a long-term metabolic disorder that is primarily characterized by insulin resistance, relative insulin deficiency and hyperglycemia.
- Trial name
- DISC (NCT02169531)
- Testing
- ex vivo Activated Immune Cells
- Where
- 2 sites in China
- Volunteers
- 25 people
- Sponsor
- B & Y Technologies
Type 1 Diabetes, Type2diabetes
Liom Non-invasive Continuous Glucose Monitor "Clinical Demo" (niCGM)
This is a single-centre, multiple cohort, open study.
- Trial name
- NCT06272136
- Testing
- Clinical Demo 2.0
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- Liom Health AG
Pre Diabetes, Vascular Stiffness
Dietary Exchanges With Avocado and Mango in Pre-diabetes
The research is designed as a randomized, 2-arm, parallel, controlled, human clinical trial to investigate the effects of avocado and mango consumption for 8 weeks on indices of macro- and micro- vascular function in individuals…
- Conditions
- Pre Diabetes, Vascular Stiffness, Vascular Dilation, Cognitive Change
- Trial name
- AVMa (NCT05353790)
- Testing
- Meals + snacks: control, Meals + snacks: Avocado mango
- Where
- United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology
it is a Group of Metabolic Diseases in, Which a Person Has High Blood Sugar, Either
Effect of Taurine on Glycemic Control in Type I and Type II Diabetic Patients
Diabetes mellitus (DM) and its vascular complications are the one of the most prevalent diseases in the state of Qatar. It is a multifactorial disease associated with the development of retinopathy, nephropathy, neuropathy…
- Conditions
- it is a Group of Metabolic Diseases in, Which a Person Has High Blood Sugar, Either, Because the Body Does Not Produce Enough Insulin,, or Because Cells do Not Respond to the Insulin That
- Trial name
- NCT01226537
- Testing
- Taurine
- Volunteers
- 20 people
- Sponsor
- Hamad Medical Corporation
PreDiabetes, Aging
Safety and Efficacy of KH-1 for Stimulating Autophagy in Non-diabetic Adults With Elevated Blood Glucose Concentration
Aging significantly impacts overall health and is a risk factor for developing diabetes. An estimated 50% of U.S. adults aged ≥65 years were reported to have prediabetes (defined as having a fasting glucose concentration of…
- Trial name
- NCT06445569
- Testing
- KH-1
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Kalin Health, LLC
Healthy Aging, Inflammaging
The Effects of Quercefit® and Ubiqsome™ in Mitigating Inflammation and Promoting Metabolic Health
The goal of this clinical trial is to learn if Quercefit® or Ubiqsome™ can improve markers of healthy aging, blood sugar control, and heart health in older adults. It will also learn about the safety of these supplements.
- Conditions
- Healthy Aging, Inflammaging, Metabolic Health, Quercetin
- Trial name
- NCT07760506
- Testing
- Quercetin (dietary supplement), Coenzyme Q10, Rice Flour
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Applied Science & Performance Institute
Diabetes Mellitus, Type 2
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
The purpose of this study is to see how well LY3938577 works and how safe it is compared to degludec in people with type 2 diabetes. Participation in the study will last about 26 weeks.
- Trial name
- NCT07215312
- Testing
- LY3938577, Degludec
- Where
- 26 sites in United States, Argentina
- Volunteers
- 100 people
- Sponsor
- Eli Lilly and Company
Diabetes, Pre-diabetes
Does Insulin Requirement Post Cardiac Surgery Predicts The Risk Of Developing Diabetes
The patient outcome in cardiac surgery is substantially linked to the occurrence of hyperglycemia. Qatar ranks 5th in the rate of diabetes globally; Moreover diabetics comprise more than 40% of patients admitted to the cardiac…
- Trial name
- NCT04765982
- Testing
- Checking diabetes development in follow up at 3 month
- Where
- Qatar
- Volunteers
- 100 people
- Sponsor
- Hamad Medical Corporation
Diabetes Mellitus, Type 2
Effects of Nateglinide vs Acarbose on Postprandial Glucose Fluctuation, Dyslipidemia, and Inflammatory Factors
This study was conducted to demonstrate superiority of nateglinide in postprandial glucose fluctuation, dyslipidemia, and inflammatory status improvement.
- Trial name
- ENERGY (NCT00928889)
- Testing
- Nateglinide 120 mg, Acarbose 50 mg
- Where
- 6 sites in China
- Volunteers
- 160 people
- Sponsor
- Novartis Pharmaceuticals
Metabolic Syndrome (MetS), Inflammation
Comparing a Healthy Beef-Centric Diet to a Healthy U.S.-Style Diet on Metabolic Health Outcomes in Pre-Diabetic Adults
This randomized study will be conducted to compare the effect of a healthy beef-centric diet to a healthy U.S.-style dietary pattern on inflammation and other metabolic health outcomes in a metabolic syndrome and/or pre-diabetic…
- Conditions
- Metabolic Syndrome (MetS), Inflammation, Pre-Diabetes
- Trial name
- NCT07269847
- Testing
- Healthy Beef-Centric Diet, Healthy U.S.-Style Dietary Pattern
- Where
- Canada
- Volunteers
- 56 people
- Sponsor
- National Cattlemen's Beef Association, a contractor to the Beef Checkoff
Vascular Diseases, Impaired Glucose Tolerance
Effects of Dietary Ingredients on Vascular Function
The main aim of the study is to investigate the effects of dietary ingredients (polyphenols and carotenoids) on vascular function during acute glucose load.
- Trial name
- NCT02158481
- Testing
- A capsule containing both polyphenols and carotenoids
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Unilever R&D
Diabetes
Effect of Glucose on QTc Interval in Type 1 Diabetes
High blood glucose levels (hyperglycaemia) and Moxifloxacin (a commonly used antibiotic) have both been shown independently to affect heart activity in healthy volunteers as recorded by ECG. i.e.
- Trial name
- NCT01984827
- Testing
- Moxifloxacin, hyper-glycaemic clamp
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- Richmond Research Institute
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Comparison of Glycemic Control Among Diabetics Using Three Different Pen Needles
Anxiety about needles is a commonly expressed concern by diabetics about beginning insulin therapy. A shorter, thinner pen needle that delivers insulin with the safety and efficacy profile of currently marketed pen needles may…
- Trial name
- NCT00928057
- Testing
- 4mm x 32G pen needle, 8mm x 31G pen needle, 5mm x 31G pen needle
- Where
- 4 sites in United States
- Volunteers
- 173 people
- Sponsor
- Becton, Dickinson and Company
Pre-diabetes
Evaluation of Video On-Demand Programming to Prevent Type 2 Diabetes in Adults
Over the past 40 years, diabetes has increased dramatically in parallel with rapid increases in obesity.About 90 to 95% of persons with diabetes have type 2 diabetes, which begins when the body becomes resistant to the hormone…
- Trial name
- Project NOT ME (NCT01768546)
- Testing
- Virtual Diabetes Prevention Program, Interactive tracking and problem solving web portal
- Volunteers
- 306 people
- Sponsor
- UnitedHealth Group
Impaired Glucose Tolerance
Voglibose Tablets 0.2 / OD Tablets 0.2 Special Drug Use Surveillance "Long-term Use in Patients With Impaired Glucose Tolerance"
The purpose of this study is to determine the safety and efficacy of long-term use of Voglibose (Basen) to prevent progression to type 2 diabetes mellitus in participants with impaired glucose tolerance in the routine clinical…
- Trial name
- NCT01993927
- Testing
- Voglibose
- Where
- Japan
- Volunteers
- 742 people
- Sponsor
- Takeda